264 related articles for article (PubMed ID: 30931336)
1. Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients.
Dornieden T; Wilde B; Korth J; Werner K; Horn PA; Witzke O; Lindemann M
J Immunol Res; 2019; 2019():3926175. PubMed ID: 30931336
[TBL] [Abstract][Full Text] [Related]
2. Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells.
Dirks J; Egli A; Sester U; Sester M; Hirsch HH
Transpl Infect Dis; 2013 Feb; 15(1):79-89. PubMed ID: 23176118
[TBL] [Abstract][Full Text] [Related]
3. The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients.
Lindemann M; Korth J; Sun M; Xu S; Struve C; Werner K; Dornieden T; Horn PA; Witzke O; Wilde B
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544783
[TBL] [Abstract][Full Text] [Related]
4. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
5. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
Banas B; Steubl D; Renders L; Chittka D; Banas MC; Wekerle T; Koch M; Witzke O; Mühlfeld A; Sommerer C; Habicht A; Hugo C; Hünig T; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Krämer BK; Krüger B
Transpl Int; 2018 Apr; 31(4):436-450. PubMed ID: 29284181
[TBL] [Abstract][Full Text] [Related]
7. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients.
Lúcia M; Crespo E; Melilli E; Cruzado JM; Luque S; Llaudó I; Niubó J; Torras J; Fernandez N; Grinyó JM; Bestard O
Clin Infect Dis; 2014 Dec; 59(11):1537-45. PubMed ID: 25048845
[TBL] [Abstract][Full Text] [Related]
8. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
10. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
11. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
Chanouzas D; Small A; Borrows R; Ball S
PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients.
Sadeghi M; Daniel V; Naujokat C; Schnitzler P; Schmidt J; Mehrabi A; Zeier M; Opelz G
Transplantation; 2008 Jul; 86(2):275-85. PubMed ID: 18645491
[TBL] [Abstract][Full Text] [Related]
16. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.
Fernández-Ruiz M; Giménez E; Vinuesa V; Ruiz-Merlo T; Parra P; Amat P; Montejo M; Paez-Vega A; Cantisán S; Torre-Cisneros J; Fortún J; Andrés A; San Juan R; López-Medrano F; Navarro D; Aguado JM;
Clin Microbiol Infect; 2019 Mar; 25(3):381.e1-381.e10. PubMed ID: 29803844
[TBL] [Abstract][Full Text] [Related]
17. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients.
Couzi L; Thiébaut R; Carron JC; Moreau JF; Merville P; Taupin JL
Transplantation; 2008 Oct; 86(8):1060-7. PubMed ID: 18946343
[TBL] [Abstract][Full Text] [Related]
18. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
[TBL] [Abstract][Full Text] [Related]
19. How immunosuppressive therapy affects T cells from kidney transplanted patients of different age: the role of latent cytomegalovirus infection.
Welzl K; Weinberger B; Kronbichler A; Sturm G; Kern G; Mayer G; Grubeck-Loebenstein B; Koppelstaetter C
Clin Exp Immunol; 2014 Apr; 176(1):112-9. PubMed ID: 24028181
[TBL] [Abstract][Full Text] [Related]
20. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]